新闻

iX Biopharma: Reports Improvement To Adjusted EBITDA & Strengthened Balance Sheet For 1H FY2026.

09 Feb 2026 11:18

Gross margin improved to 26%...

Attachments:

• iX_Biopharma1H26_Results_-_Press_Release.pdf

Source: ShareInvestor Express